How does NCI support the field of proteomics and its potential to advance cancer research?
NCI currently funds proteomics programs both intramurally (within NCI) and extramurally (within the larger research community). Clinical Proteomic Technologies for Cancer Initiative In 2006, NCI launched the Clinical Proteomic Technologies for Cancer (CPTC) initiative (http://proteomics.cancer.gov), a 5-year technology development program that harnesses the expertise of investigators in academic institutions around the country. The CPTC was founded to accelerate the development of better technology for proteomics research in response to scientists’ needs for more accurate, more standardized, and more reproducible protein measurement techniques. The CPTC is composed of three major, integrated programs: • The Clinical Proteomic Technology Assessment for Cancer (CPTAC) network, a collaborative effort involving both the public and private sectors, is conducting rigorous assessments of two major technologies currently used to analyze proteins and peptides—mass spectrometry and affinity capt
